Pentoxifylline
Pentoxifylline (pentoxifylline) is a small molecule pharmaceutical. Pentoxifylline was first approved as Trental on 1984-08-30. It is used to treat brain ischemia, cerebral malaria, diabetic angiopathies, diabetic neuropathies, and gangrene amongst others in the USA. It is known to target adenosine receptor A2b.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Pentoxifylline (discontinued: Pentoxifylline, Pentoxil, Trental)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pentoxifylline
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRENTAL | Validus Pharmaceuticals | N-018631 DISCN | 1984-08-30 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| betamethasone dipropionate 0.05% / minoxidil 5% / niacinamide 2% / pentoxifylline 0.5% | unapproved drug other | 2019-05-08 |
| pentoxifylline | ANDA | 2026-09-16 |
| pentoxifylline 0.5% / triamcinolone acetonide 0.1% | unapproved drug other | 2019-05-14 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
200 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic renal insufficiency | D051436 | — | N18 | — | 2 | 5 | 3 | 3 | 12 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 3 | 4 | 3 | 3 | 12 |
| Alcoholic hepatitis | D006519 | EFO_1001345 | K70.1 | 1 | 2 | 4 | 2 | 2 | 10 |
| Hepatitis | D006505 | — | K75.9 | 2 | 4 | 4 | 1 | 1 | 9 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 2 | 4 | 4 | 1 | 1 | 9 |
| Fibrosis | D005355 | — | — | — | 6 | 2 | 1 | — | 9 |
| Syndrome | D013577 | — | — | 1 | 1 | 2 | 1 | 3 | 7 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 2 | 2 | 3 | — | 6 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 2 | 2 | 2 | 1 | 6 |
| Infertility | D007246 | EFO_0000545 | — | 1 | 1 | 2 | 1 | 1 | 6 |
Show 36 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 8 | 2 | — | — | 9 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 3 | 2 | — | — | 4 |
| Covid-19 | D000086382 | — | U07.1 | 1 | 2 | 1 | — | 2 | 4 |
| Leishmaniasis | D007896 | EFO_0005044 | B55 | — | 4 | 3 | — | — | 4 |
| Peripheral nervous system diseases | D010523 | — | G64 | 1 | 2 | 1 | — | 1 | 4 |
| Osteonecrosis | D010020 | EFO_0004259 | M87 | — | — | 1 | — | 2 | 3 |
| Radiation injuries | D011832 | — | T66 | — | 2 | 1 | — | — | 3 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | 1 | — | 2 | 3 |
| Cutaneous leishmaniasis | D016773 | — | B55.1 | — | 3 | 2 | — | — | 3 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | 2 | — | 1 | — | — | 3 |
Show 42 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | 3 | 3 | — | — | 1 | 5 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 3 | 3 | — | — | 1 | 5 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 2 | 3 | — | — | 1 | 4 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 3 | — | — | — | 3 |
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | 1 | — | — | 1 | 3 |
| Lymphedema | D008209 | — | Q82.0 | — | 3 | — | — | — | 3 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | 3 | — | — | — | 3 |
| Asthenozoospermia | D053627 | — | — | — | 1 | — | — | 2 | 3 |
| Behcet syndrome | D001528 | EFO_0003780 | M35.2 | — | 2 | — | — | — | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 2 | — | — | — | 2 |
Show 51 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatopulmonary syndrome | D020065 | EFO_1001346 | K76.81 | 1 | — | — | — | 2 | 3 |
| Alopecia areata | D000506 | EFO_0004192 | L63 | 1 | — | — | — | 1 | 2 |
| Alopecia | D000505 | — | L64 | 1 | — | — | — | 1 | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | — | — | 1 | — | — | — | — | 1 |
| Nervous system neoplasms | D009423 | — | — | 1 | — | — | — | — | 1 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | — | — | — | — | 1 |
| Crohn disease | D003424 | EFO_0000384 | K50 | 1 | — | — | — | — | 1 |
| Mucositis | D052016 | EFO_1001898 | — | 1 | — | — | — | — | 1 |
| Maximum tolerated dose | D020714 | — | — | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ulcer | D014456 | MPATH_579 | — | — | — | — | — | 2 | 2 |
| Leg ulcer | D007871 | — | — | — | — | — | — | 2 | 2 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 2 | 2 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 2 | 2 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | — | 2 | 2 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | — | 2 | 2 |
| Tennis elbow | D013716 | EFO_1001896 | M77.1 | — | — | — | — | 2 | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 1 | 1 |
| Venous insufficiency | D014689 | — | — | — | — | — | — | 1 | 1 |
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | — | — | — | 1 | 1 |
Show 32 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pentoxifylline |
| INN | pentoxifylline |
| Description | Pentoxifylline is an oxopurine. |
| Classification | Small molecule |
| Drug class | theophylline derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O |
Identifiers
| PDB | — |
| CAS-ID | 6493-05-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL628 |
| ChEBI ID | 7986 |
| PubChem CID | 4740 |
| DrugBank | DB00806 |
| UNII ID | SD6QCT3TSU (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Pentoxifylline
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,096 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use